Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bitong Capsule
- Development stage
- Phase 1
- Lead developer
- PT Sinar Herba Radix
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Bitong Capsule is a traditional Chinese medicine (TCM) developed by Jinan Kangzhong Pharmaceutical Technology Development Co., Ltd. for the treatment of allergic rhinitis. It is formulated as an oral capsule and has undergone Phase I clinical evaluation in China to assess its safety, tolerability, and pharmacokinetic profile in healthy volunteers. As a botanical-based therapy, it is designed to alleviate symptoms of nasal congestion and inflammation associated with allergic rhinitis through the synergistic action of its herbal components.
- Brand names
- Bitong Capsule
Beyond the preview
Go deeper on Bitong Capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bitong Capsule.